Abstract
In the RATIONALE-307 trial (NCT03594747), tislelizumab plus platinum-based chemotherapy significantly improved clinical outcomes vs chemotherapy alone in treatment-naïve advanced squamous non-small cell lung cancer (sq-NSCLC). Previously, we showed superior clinical efficacy of tislelizumab plus chemotherapy vs chemotherapy alone regardless of PD-L1 expression (J Clin Oncol 38:2020[suppl; Abstr 9554]) and blood tumor mutational burden (Ann Oncol 2020;31[4):S754–S840). Here we report the updated biomarker analysis of PD-L1 expression, tissue tumor mutational burden (tTMB) and gene expression profiling (GEP) in baseline tumor samples.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
